L’Oréal Faces MDL Petition Over Benzene-Contaminated Acne Treatments

L’Oréal Faces MDL Petition Over Benzene-Contaminated Acne Treatments

THE WHAT?  L’Oréal is grappling with six class action lawsuits concerning CeraVe and other benzoyl peroxide acne treatments, which are alleged to contain cancer-causing benzene. Plaintiffs claim that benzene levels in these products far exceed federal safety standards, raising serious health concerns.

THE DETAILS The lawsuits follow a March 2024 report by independent testing lab Valisure, which identified benzene contamination in various acne treatments, including CeraVe, ProActive, and Clinique. Benzoyl peroxide, a widely used ingredient in acne products, is said to react in ways that form benzene—a carcinogen linked to numerous cancers, including leukemia and lymphoma.

A previous JPML attempt to consolidate similar claims in August 2024 was rejected due to the diversity of products and manufacturers. However, a revised motion filed in late November seeks to consolidate claims solely against L’Oréal in the District of Hawaii. The decision could shape the trajectory of these legal battles.

THE WHY? With benzoyl peroxide being a staple in acne treatments, the allegations against L’Oréal highlight potential regulatory and consumer trust challenges for the broader skincare industry.

JOBS & PEOPLE

TRAVEL

PROFESSIONAL BEAUTY